Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31401405 | 0.86 | MAPT (0.40) | MAPTHTTHPGDALDH1A1POLB | |
| SCHEMBL31401324 | 0.86 | MAPT (0.40) | MAPTHTTHPGDALDH1A1POLB | |
| SCHEMBL2276882 | 0.78 | HTT (0.36) | MAPTHTTLMNABLMHPGD | |
| SCHEMBL21603112 | 0.77 | LMNA (0.33) | MAPTHTTLMNABLM | |
| SCHEMBL8889457 | 0.76 | TAAR1 (0.44) | ALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL31401440 | 0.76 | TSHR (0.39) | HTTALDH1A1L3MBTL1 | |
| SCHEMBL20522658 | 0.75 | USP2 (0.35) | MAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL28917603 | 0.75 | ALDH1A1 (0.40) | MAPTHTTHPGDALDH1A1L3MBTL1 | |
| SCHEMBL8250970 | 0.72 | TSHR (0.40) | HTR2CHTR2B | |
| SCHEMBL30623726 | 0.72 | MAPT (0.40) | MAPTHTTHPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |